Bernard Walter Balleine

Title: Bernard Walter Balleine: Innovator in Neuromuscular and Neuroinflammatory Treatments

Introduction

Bernard Walter Balleine is a notable inventor based in Paddington, Australia. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that target neuromuscular and neuroinflammatory diseases. His innovative work has the potential to improve the quality of life for both humans and animals.

Latest Patents

Balleine holds a patent for "Haloallylamine dual amine oxidase inhibitors." This invention relates to novel compounds capable of inhibiting semicarbazide-sensitive amine oxidase (SSAO/VAP-1) and monoamine oxidase B (MAO-B). These compounds are particularly useful in treating a variety of neuromuscular diseases, such as muscular dystrophies, as well as neuroinflammatory diseases affecting both peripheral and central systems in human subjects, pets, and livestock. The patent also encompasses pharmaceutical compositions containing these compounds and various applications thereof.

Career Highlights

Balleine is associated with Syntara Limited, where he continues to advance his research and development efforts. His work is characterized by a commitment to addressing complex medical challenges through innovative solutions.

Collaborations

Some of his notable coworkers include Alan Duncan Robertson and Alison Dorothy Findlay. Their collaborative efforts contribute to the ongoing success and impact of Balleine's research.

Conclusion

Bernard Walter Balleine's contributions to the field of pharmaceutical sciences exemplify the importance of innovation in addressing critical health issues. His work not only advances scientific knowledge but also holds promise for practical applications in treating various diseases.